Literature DB >> 8422341

Arterial intimal hyperplasia after occlusion of the adventitial vasa vasorum in the pig.

S G Barker1, A Talbert, S Cottam, P A Baskerville, J F Martin.   

Abstract

Oxygenation of the arterial wall is provided by diffusion of oxygen outward from the main vessel lumen and inward from the adventitial vasa vasorum. In a group of four Yucatan miniature pigs the oxygenation profiles across the superficial femoral arteries were recorded by polarographic oxygen microelectrodes. The profiles obtained suggested a relatively poorly oxygenated media (a trough value of approximately 25% that of the intimal oxygenation) with a progressive rise in oxygenation toward the intimal and adventitial surfaces. In four other survival experiments, occlusion of the adventitial vasa vasorum by flush ligation of the arterial branches that supply them resulted in the production of a focal, intimal hyperplastic lesion that was absent in control vessels (intimal to medial ratios [mean +/- SEM] of 0.053 +/- 0.008, n = 8, p < 0.001 and 0.013 +/- 0.001, n = 8, respectively). By electron microscopy this lesion was seen to be composed mainly of smooth muscle cells. This evidence would support the hypothesis that arterial wall hypoxia may be involved in the initiation of intimal hyperplasia. It is proposed that human atherosclerosis may be initiated by occlusion of the vasa vasorum and concomitant hypoxia.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8422341     DOI: 10.1161/01.atv.13.1.70

Source DB:  PubMed          Journal:  Arterioscler Thromb        ISSN: 1049-8834


  21 in total

1.  Formation of new vasa vasorum in vasculitis. Production of angiogenic cytokines by multinucleated giant cells.

Authors:  M Kaiser; B Younge; J Björnsson; J J Goronzy; C M Weyand
Journal:  Am J Pathol       Date:  1999-09       Impact factor: 4.307

Review 2.  Evaluation of microvascular anatomy by micro-CT.

Authors:  A Lerman; E L Ritman
Journal:  Herz       Date:  1999-11       Impact factor: 1.443

Review 3.  The dynamic vasa vasorum.

Authors:  Erik L Ritman; Amir Lerman
Journal:  Cardiovasc Res       Date:  2007-06-29       Impact factor: 10.787

4.  150-kD oxygen-regulated protein is expressed in human atherosclerotic plaques and allows mononuclear phagocytes to withstand cellular stress on exposure to hypoxia and modified low density lipoprotein.

Authors:  Y Tsukamoto; K Kuwabara; S Hirota; J Ikeda; D Stern; H Yanagi; M Matsumoto; S Ogawa; Y Kitamura
Journal:  J Clin Invest       Date:  1996-10-15       Impact factor: 14.808

5.  Enhanced coronary vasa vasorum neovascularization in experimental hypercholesterolemia.

Authors:  H M Kwon; G Sangiorgi; E L Ritman; C McKenna; D R Holmes; R S Schwartz; A Lerman
Journal:  J Clin Invest       Date:  1998-04-15       Impact factor: 14.808

Review 6.  The vasa vasorum in diseased and nondiseased arteries.

Authors:  Mary Jo Mulligan-Kehoe
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-11-25       Impact factor: 4.733

7.  Low vasa vasorum densities correlate with inflammation and subintimal thickening: potential role in location--determination of atherogenesis.

Authors:  M Gössl; D Versari; L O Lerman; A R Chade; P E Beighley; R Erbel; E L Ritman
Journal:  Atherosclerosis       Date:  2009-03-25       Impact factor: 5.162

8.  Local delivery of dexamethasone for prevention of neointimal proliferation in a rat model of balloon angioplasty.

Authors:  A E Villa; L A Guzman; W Chen; G Golomb; R J Levy; E J Topol
Journal:  J Clin Invest       Date:  1994-03       Impact factor: 14.808

9.  Angiogenesis in human coronary atherosclerotic plaques.

Authors:  E R O'Brien; M R Garvin; R Dev; D K Stewart; T Hinohara; J B Simpson; S M Schwartz
Journal:  Am J Pathol       Date:  1994-10       Impact factor: 4.307

10.  The effect of the ETA receptor antagonist, FR 139317, on [125I]-ET-1 binding to the atherosclerotic human coronary artery.

Authors:  M R Dashwood; S P Allen; T N Luu; J R Muddle
Journal:  Br J Pharmacol       Date:  1994-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.